Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Opioid Receptors Influence Ischemia-Reperfusion Injury
This study has been suspended.
Sponsored by: Radboud University
Information provided by: Radboud University
ClinicalTrials.gov Identifier: NCT00184938
  Purpose

The most powerful protective mechanism against ischemia-reperfusion injury other than rapid reperfusion is ischemic preconditioning. Ischemic preconditioning is defined as the development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia resulting in a marked reduction in infarct size. This mechanism can be mimicked by several pharmacological substances such as adenosine and morphine.

We, the researchers at Radboud University Nijmegen Medical Centre, have recently developed a method in which we can detect ischemia-reperfusion injury in the human forearm by using Annexin A5 scintigraphy (Rongen et al). With this method we will determine whether opioid receptors are involved in ischemic preconditioning. We expect to find that morphine can mimic ischemic preconditioning and that acute ischemic preconditioning can be blocked with the opioid receptor antagonist naloxon. This study will increase our knowledge about the mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous protective mechanism in a clinical setting.


Condition Intervention
Ischemia-Reperfusion Injury
Drug: morphine
Drug: naloxone
Drug: Technetium-TC99m-labeled Annexin A5
Procedure: forearm ischemic exercise
Procedure: ten minute forearm ischemia

Drug Information available for: Naloxone Naloxone hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Double-Blind, Placebo Control, Crossover Assignment
Official Title: Opioid Induced Acute Preconditioning

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Percentual difference in Annexin A5 targetting between the experimental and control arm 1 and 4 hours after intravenous injection

Estimated Enrollment: 40
Study Start Date: January 2005
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers

Exclusion Criteria:

  • Exposition to radiation due to imaging techniques in the previous five years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00184938

Locations
Netherlands, Gelderland
Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology
Nijmegen, Gelderland, Netherlands, 6500 HB
Sponsors and Collaborators
Radboud University
Investigators
Principal Investigator: Gerard Rongen, MD, Phd Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology
  More Information

Publications:
Study ID Numbers: OPIRI
Study First Received: September 12, 2005
Last Updated: March 27, 2008
ClinicalTrials.gov Identifier: NCT00184938  
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
opioids
ischemic preconditioning
morphine

Study placed in the following topic categories:
Morphine
Postoperative Complications
Vascular Diseases
Annexin A5
Ischemia
Naloxone
Reperfusion Injury

Additional relevant MeSH terms:
Pathologic Processes
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Cardiovascular Diseases
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 14, 2009